Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - PR Newswire

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma    PR Newswire HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma    Yahoo! Finance Canada NMPA approves fruquintinib-sintilimab combo for kidney cancer By Investing.com    Investing.com Canada Innovent Wins China Approval for TYVYT–ELUNATE Combo in Advanced Kidney Cancer    TipRanks Why HUTCHMED (China) Shares Are Climbing Now    TipRanks

Original source: Google News